- Conditions
- Hodgkin Lymphoma
- Interventions
- PLX3397
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Chicago, Illinois • Rochester, Minnesota + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–20
of 20
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- CGT9486, Pexidartinib, Sunitinib
- Drug
- Lead sponsor
- Cogent Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 6
- States / cities
- Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
- Conditions
- Acute Graft Versus Host Disease, Steroid Refractory Graft Versus Host Disease
- Interventions
- BRD4 Inhibitor PLX51107
- Drug
- Lead sponsor
- Hannah Choe, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Metastatic Breast Cancer
- Interventions
- PLX3397, Eribulin
- Drug
- Lead sponsor
- Hope Rugo, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 3
- States / cities
- San Francisco, California • Durham, North Carolina • Nashville, Tennessee
- Conditions
- Rheumatoid Arthritis
- Interventions
- PLX5622, Placebo
- Drug
- Lead sponsor
- Plexxikon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 4
- States / cities
- Anniston, Alabama • Lansing, Michigan • Duncansville, Pennsylvania + 1 more
- Conditions
- Healthy
- Interventions
- PLX5622, Placebo
- Drug
- Lead sponsor
- Plexxikon
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Acute Myeloid Leukemia
- Interventions
- PLX3397
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 9
- States / cities
- San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 5 more
- Conditions
- Patients With Newly Diagnosed Glioblastoma
- Interventions
- PLX3397, Radiation Therapy, Temozolomide
- Drug · Radiation
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Detroit, Michigan + 4 more
- Conditions
- Solid Tumor, Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations, Tenosynovial Giant Cell Tumor
- Interventions
- PLX7486 TsOH
- Drug
- Lead sponsor
- Plexxikon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Solid Tumor
- Interventions
- PLX3397
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 8 more
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST), Ovarian Cancer
- Interventions
- PLX3397, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 7 more
- Conditions
- V600-mutated BRAF Unresectable Melanoma, V600-mutated BRAF Metastatic Melanoma, Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor
- Interventions
- PLX3397, vemurafenib
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Aurora, Colorado • Nashville, Tennessee + 1 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- PLX3397
- Drug
- Lead sponsor
- Plexxikon
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 5
- States / cities
- Tuscaloosa, Alabama • Little Rock, Arkansas • San Francisco, California + 2 more
- Conditions
- Malignant Melanoma, Colorectal Carcinoma
- Interventions
- PLX4032
- Drug
- Lead sponsor
- Plexxikon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 5
- States / cities
- Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 2 more
- Conditions
- Gastrointestinal Stromal Tumor (GIST)
- Interventions
- MEK162, Pexidartinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Solid Tumors
- Interventions
- PLX3397, Paclitaxel
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 5 more
- Conditions
- Solid Tumors, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Interventions
- PLX51107
- Drug
- Lead sponsor
- Plexxikon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 5
- States / cities
- New York, New York • Columbus, Ohio • Philadelphia, Pennsylvania + 2 more
- Conditions
- Prostate Cancer
- Interventions
- PLX3397
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Solid Tumors, Tenosynovial Giant Cell Tumor, Synovitis, Pigmented Villonodular
- Interventions
- PLX73086
- Drug
- Lead sponsor
- Plexxikon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Detroit, Michigan • San Antonio, Texas
- Conditions
- Recurrent Glioblastoma
- Interventions
- PLX3397
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more